RedHill Biopharma has announced successful final results from the first Phase III clinical study with RHB 105 for the eradication...
The FDA has given 510(K) approval to Ventana anti-Helicobacter pylori (SP48) Rabbit Monoclonal Primary Antibody (H. pylori), from Ventana Medical...
Treating Helicobacter pylori (H. pylori) infection of the stomach could lead to a marked reduction in the risk of stomach cancer – particularly in the elderly.
RedHill Biopharma has announced positive top-line results from its Phase III study with RHB 105 for the treatment of Helicobacter...
Helicobacter pylori infection leads to chronic gastritis and increased risk of gastric cancer.
RedHill Biopharma announced that the FDA has approved Talicia (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg1/250 mg/12.5 mg...
Objectives: Rising trends in eosinophilic esophagitis (EoE) have been repeatedly linked to declining Helicobacter pylori (H. pylori) infection, mostly in retrospective studies. We aimed to prospectively evaluate this inverse association.
Phathom Pharmaceuticals, Inc. announced the FDA approved both Voquezna Triple Pack (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and Voquezna Dual Pack (vonoprazan tablets, amoxicillin capsules), for the treatment of Helicobacter pylori (H. pylori) infection in adults.